Scinai Immunotherapeutics Ltd (SCNI) - Total Liabilities
Based on the latest financial reports, Scinai Immunotherapeutics Ltd (SCNI) has total liabilities worth $3.52 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Scinai Immunotherapeutics Ltd - Total Liabilities Trend (2000–2025)
This chart illustrates how Scinai Immunotherapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. See SCNI working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Scinai Immunotherapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of Scinai Immunotherapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ULTRA LITHIUM
F:QFB
|
Germany | €2.85 Million |
|
Eason Technology Limited
NYSE MKT:DXF
|
USA | $37.62 Million |
|
NamR SA
PA:ALNMR
|
France | €9.46 Million |
|
Modiin Energy-Limited Partnership
TA:MDIN-L
|
Israel | ILA834.00K |
|
Silver Spruce Resources Inc
V:SSE
|
Canada | CA$533.19K |
|
Univa Foods Limited
NSE:UNIVAFOODS
|
India | Rs10.79 Million |
Liability Composition Analysis (2000–2025)
This chart breaks down Scinai Immunotherapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SCNI market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Scinai Immunotherapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Scinai Immunotherapeutics Ltd (2000–2025)
The table below shows the annual total liabilities of Scinai Immunotherapeutics Ltd from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.52 Million | +1.50% |
| 2024-12-31 | $3.47 Million | -84.25% |
| 2023-12-31 | $22.04 Million | -23.54% |
| 2022-12-31 | $28.83 Million | -7.17% |
| 2021-12-31 | $31.05 Million | +39.58% |
| 2020-12-31 | $22.25 Million | -57.51% |
| 2019-12-31 | $52.36 Million | +42.86% |
| 2018-12-31 | $36.65 Million | +401.21% |
| 2017-12-31 | $7.31 Million | +526.88% |
| 2016-12-31 | $1.17 Million | -41.45% |
| 2015-12-31 | $1.99 Million | +313.95% |
| 2014-12-31 | $481.23K | -9.16% |
| 2013-12-31 | $529.76K | +94.35% |
| 2012-12-31 | $272.58K | -39.54% |
| 2011-12-31 | $450.86K | -39.24% |
| 2010-12-31 | $742.07K | +44.75% |
| 2009-12-31 | $512.67K | +159.22% |
| 2008-12-31 | $197.78K | -94.94% |
| 2007-12-31 | $3.91 Million | +1527.92% |
| 2006-12-31 | $240.00K | -62.67% |
| 2005-12-31 | $643.00K | -38.47% |
| 2004-12-31 | $1.04 Million | -41.85% |
| 2003-12-31 | $1.80 Million | +11.48% |
| 2002-12-31 | $1.61 Million | +32140.00% |
| 2001-12-31 | $5.00K | -81.48% |
| 2000-12-31 | $27.00K | -- |
About Scinai Immunotherapeutics Ltd
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's s… Read more